Hepatotoxicity and liver disease in the context of HIV therapy

Current Opinion in HIV and AIDS

Volumn 2, Issue 4, 2007, Pages 306-313

  Vogel, Martin ^a   Rockstroh, Jürgen K ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Antiretroviral therapy; Drug related liver injury; HIV

Indexed keywords

ABACAVIR; AMINOTRANSFERASE; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; FATTY LIVER; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTIOUS HEPATITIS; JAUNDICE; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; MORTALITY; PATIENT INFORMATION; PRIORITY JOURNAL; RASH; REVIEW;

EID: 34250685646     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3281ca6fd2     Document Type: Review

References (59)

1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
2. Mocroft A, Phillips AN, Soriano V, et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005; 21:743-752.
3. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417-422.
4. Clark SJ, Creighton S, Portmann B, et al. Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. J Hepatol 2002; 36:295-301.
5. Puoti M, Torti C, Ripamonti D, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003; 32:259-267.
6. Lichterfeld M, Fischer HP, Spengler U, Rockstroh JK. Fatty liver and increased serum lactate in a woman with HIV. Dtsch Med Wochenschr 2003; 128:81-84.
7. Lee H, Hanes J, Johnson KA. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003; 42:14711-14719.
8. Laguno M, Milinkovic A, de Lazzari E, et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther 2005; 10:423-429.
9. Cornejo-Juarez P, Sierra-Madero J, Volkow-Fernandez P. Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment. Arch Med Res 2003; 34:64-69.
10. Ter Hofstede HJ, De Marie S, Foudraine NA, et al. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000; 11:611-616.
11. Vrouenraets SM, Treskes M, Regez RM, et al. Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment. Antivir Ther 2002; 7:239-244.
12. Bani-Sadr F, Carrat F, Rosenthal E, et al. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. Clin Infect Dis 2005; 41:1806-1809.
13. Lebrecht D, Vargas-Infante YA, Setzer B, et al. Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. Hepatology 2007; 45:72-79. Zalcitabine induced mtDNA depletion in murine liver with consequent respiratory chain dysfunction, upregulated synthesis of reactive oxygen species and microvesicular steatohepatitis. Uridine supplementation attenuated this mitochondrial hepatotoxicity without apparent intrinsic effects.
14. Walker UA, Venhoff N, Koch EC, et al. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 2003; 8:463-470.
15. Pharmacia and Upjohn Company. US prescribing information: Rescriptor. La Jolla, CA, USA, 2006.
16. Boehringer Ingelheim. US prescribing information: Viramune. Ridgefield, CT, USA, 2005.
17. GlaxoSmithKline. US prescribing information: Ziagen. Research Triangle Park, NC, USA, 2002.
18. Bristol-Myers Squibb. US prescribing information: Sustiva. Princeton, NJ, USA, 2007.
19. GlaxoSmithKline. US prescribing information: Lexiva. Research Triangle Park, NC, USA, 2007.
20. Bristol-Myers Squibb. US prescribing information: Reyataz. Princeton, NJ, USA, 2006.
21. Ortho Biotech Products. US prescribing information: Prezista. Bridgewater, NJ, USA, 2006.
22. Lucas A, Nolan D, Mallal S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother 2007; 59:591-593. This article discusses the issues of pharmacogenetic screening, in the light of the strong genetic association of the HLA-B*5701 allele and the susceptibility to developing abacavir hypersensitivity reactions.
23. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19:97-99.
24. Boehringer Ingelheim. Dear Health Care Professional. Re: Clarification of risk factors for severe, life-threatening and fatal hepatotoxicity with VIRAMUNE® (nevirapine). Ridgefield, CT, USA, 2004.
25. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35:538-539.
26. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
27. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 2005; 330:326-335.
28. Marks KM, Petrovic LM, Talal AH, et al. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 2005; 192:1943-1949.
29. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19:585-592.
30. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43:365-372.
31. Bani-Sadr F, Carrat F, Bedossa P, et al. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS 2006; 20:525-531. The largest cross-sectional study to date investigating hepatic steatosis in HIV/HCV-co-infected patients. Steatosis was present in 61% of biopsies. Factors independently associated with steatosis were body mass index and HCV viral load in patients with HCV genotype 3 infection and the mean Metavir fibrosis score, body mass indes and ferritin in patients with HCV genotype 1 infection.
32. Monto A, Dove LM, Bostrom A, et al. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C mono-infection. Hepatology 2005; 42:310-316.
33. Lemoine M, Barbu V, Girard PM, et al. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 2006; 20:387-395. An important study revealing the possible pathomechanisms of HAART-related hepatosteatosis. Liver biopsies were obtained in HIV-infected individuals under HAART with unexplained liver transaminase elevation, and the expression of sterol regulator proteins within the liver were studied.
34. Riddle TM, Kuhel DG, Woollett LA, et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001; 276:37514-37519.
35. Williams K, Rao YP, Natarajan R, et al. Indinavir alters sterol and fatty acid homeostatic mechanisms in primary rat hepatocytes by increasing levels of activated sterol regulatory element-binding proteins and decreasing cholesterol 7alpha-hydroxylase mRNA levels. Biochem Pharmacol 2004; 67:255-267.
36. Rodriguez-Novoa S, Barreiro P, Jimenez-Nacher I, Soriano V. Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J 2006; 6:234-245. A concise review on the state of pharmacogenetics in HIV therapy.
37. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genom 2005; 15:1-5.
38. Kappelhoff BS, Van Leth F, Robinson PA, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 2005; 10:489-498.
39. Ritchie MD, Haas DW, Motsinger AA, et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 2006; 43:779-782. The MDR1 polymorphism (encoding pGP) 3435T was associated with a decreased risk, whereas the CYP2B6 516G→T polymorphism (which would suggest a pharmacokinetic effect) was not associated with any risk of hepatotoxicity under nevirapine exposure.
40. Merck and Co. Inc. US prescribing informatin: Crixivan. Whitehouse Station, NJ, USA, 2006.
41. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42:418-427.
42. Cicconi P, Cozzi-Lepri A, Phillips A, et al. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS 2007; 21:599-606. In contrast to previous findings of this group (see ref. [52] and Table 2) this analysis focused on periods off HAART versus on HAART, thereby paying more attention to the fluctuations in ALT levels before the start of HAART. The authors concluded that HAART per se is not a risk factor for transaminase elevations in hepatitis coinfected patients.
43. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
44. Benhamou Y, Mats V, Walczak D. Systemic overview of HAART-associated liver enzyme elevations in patients infected with HIV and co-infected with HCV. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5-8 February 2006. Abstract 88.
45. Bonfanti P, Landonio S, Ricci E, et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:316-318.
46. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe d'Epidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS 1999; 13:F115-F121.
47. Monforte Ade A, Bugarini R, Pezzotti P, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001; 28:114-123.
48. Aceti A, Pasquazzi C, Zechini B, De Bac C. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29:41-48.
49. Saves M, Raffi F, Clevenbergh P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother 2000; 44:3451-3455.
50. Sulkowski MS, Mehta SH, Chaisson RE, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18:2277-2284.
51. Servoss JC, Kitch DW, Andersen JW, et al. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr 2006; 43:320-323. Probably the largest study on the incidence and associated risk factors of antiretroviral drug-related liver injury to date. For details refer to Table 2.
52. Torti C, Lapadula G, Casari S, et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-Master Cohort. BMC Infect Dis 2005; 5:58.
53. Sulkowski M, Rockstroh J, Soriano V, et al. Clinical course of increased LFTs and hepatic events associated with ritonavir (RTV)-boosted tipranavir (TPV/r) based therapy in the RESIST trials. In: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27-30 September 2006. Abstract H-1899.
54. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713.
55. Mocroft A, Rockstroh J, Soriano V, et al. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antivir Ther 2005; 10:779-790.
56. Sheng W, Hung C, Kao J, et al. Clinical and virologic efffect of chronic hepatitis D virus infection on patients with hepatitis B and HIV co-infection in the era of HAART. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5-8 February 2006. Abstract 838.
57. Torti C, Lapadula G, Puoti M, et al. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-Master Cohort. J Acquir Immune Defic Syndr 2006; 41:180-185. A large analysis investigating risk factors among HCV-co-infected patients commencing HAART. Multivariate analysis showed that male sex, HCV genotype 3, hepatitis B co-infection, higher ALT and lower CD4 cell count at baseline were independent predictors of severe hepatotoxicity.
58. Casado J, Aranzabal L, Moya J, et al. HAART-associated hepatotoxicity in HIV/HCV-co-infected patients with cirrhosis. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5-8 February 2006. Abstract 889.
59. Torti C, Lapadula G, Uccelli MC, et al. Influence of viral chronic hepatitis coinfection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. Int J Antimicrob Agents 2007; 29:185-190.